GlaxoSmithKline said it would buy cancer-focused drug company Tesaro for about $4.16 billion, positioning the health-care giant in a promising, but fiercely competitive, area of medicine.

Tesaro is exploring a sale, according to people familiar with the matter, two months after the cancer-treatment developer won a key drug approval. Company, ...

Shares of Tesaro Inc. shot up over 58% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by GlaxoSmithKline PLC for $5.1 billion in cash. Glaxo's stock fell 3.3% ...

When Tesaro Inc. announced Monday afternoon that the U.S. Food and Drug Administration had approved its ovarian cancer drug, the company said it would wait to announce the drug’s price until ...

Tesaro is making a move into the hot cancer immunotherapy field, paying $17 million upfront and offering milestones worth hundreds of millions more to work with AnaptysBio on a portfolio of ...

The FDA has given Tesaro a green light to start marketing rolapitant to help prevent some of the common side effects of chemotherapy. ... setting up the regulatory package and today's approval.

Tesaro, Inc. (NASDAQ: TSRO) is watching its shares make a significant gain on Wednesday after the company released positive late-stage trial results. The company announced that its Phase 3 NOVA ...

Investors in Tesaro, Inc. TSRO need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 20, 2017 $70.00 Put had some of the highest implied ...

Tesaro's experimental ovarian cancer drug niraparib proved to significantly lengthen progression-free survival time in patients during a recent Stage 3 trial.

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.

Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares ...